Correlation Between B-Cell Activating Factor of the Tumor Necrosis Factor Family Level in Serum and Immune Inflammation in Patients with Neuropsychiatric Systemic Lupus Erythematosus and its Clinical Value

References

• Aguirre-Valencia, D., Rios-Serna, L. J., Posso-Osorio, I., Naranjo-Escobar, J., Lopez, D., Bedoya-Joaqui, V., Nieto-Aristizábal, I., Castro, A. M., Díaz-Ordoñez, L., Navarro, E. P., Barrera, M. C., Echeverri, A., Cañas, C. A., & Tobón, G. J. (2020). Expression of BAFF, APRIL, and cognate receptor genes in lupus nephritis and potential use as urinary biomarkers. Journal Translational Autoimmunity, 3, 100027. https://doi.org/10.1016/j.jtauto.2019.100027
   PubMedGoogle Scholar
• Alcocer-Varela, J., Aleman-Hoey, D., & Alarcon-Segovia, D. (1992). Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus, 1(2), 111–117. https://doi.org/10.1177/096120339200100209
   PubMed Web of Science ®Google Scholar
• Bhatnagar, H., Kala, S., Sharma, L., Jain, S., Kim, K. S., & Pal, R. (2011). Serum and organ-associated anti-hemoglobin humoral autoreactivity: Association with anti-sm responses and inflammation. European Journal of Immunology, 41(2), 537–548. https://doi.org/10.1002/eji.201040989
   PubMed Web of Science ®Google Scholar
• Boomer, J. S., To, K., Chang, K. C., Takasu, O., Osborne, D. F., Walton, A. H., Bricker, T. L., Jarman, S. D., Kreisel, D., Krupnick, A. S., Srivastava, A., Swanson, P. E., Green, J. M., & Hotchkiss, R. S. (2011). Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA, 306(23), 2594–2605. https://doi.org/10.1001/jama.2011.1829
   PubMed Web of Science ®Google Scholar
• Carrion-Barbera, I., Salman-Monte, T. C., Vilchez-Oya, F., & Monfort, J. (2021). Neuropsychiatric involvement in systemic lupus erythematosus: A review. Autoimmunity Reviews, 20(4), 102780. https://doi.org/10.1016/j.autrev.2021.102780
   PubMed Web of Science ®Google Scholar
• Chatham, W. W., Furie, R., Saxena, A., Brohawn, P., Schwetje, E., Abreu, G., & Tummala, R. (2021). Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: Results of a phase II open-label extension study. Arthritis and Rheumatology, 73(5), 816–825. https://doi.org/10.1002/art.41598
   PubMed Web of Science ®Google Scholar
• Fernandez-Ruiz, R., Blank, R. B., Wu, M., & Belmont, H. M. (2021). C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature. Lupus, 30(10), 1671–1678. https://doi.org/10.1177/09612033211027938
   PubMed Web of Science ®Google Scholar
• Fortuna, G., & Brennan, M. T. (2013). Systemic lupus erythematosus: Epidemiology, pathophysiology, manifestations, and management. Dental Clinics of North America, 57(4), 631–655. https://doi.org/10.1016/j.cden.2013.06.003
   PubMedGoogle Scholar
• Gardam, S., & Brink, R. (2014). Non-canonical NF-kappaB signaling initiated by BAFF influences B cell biology at multiple junctures. Frontiers in Immunology, 4, 509. https://doi.org/10.3389/fimmu.2013.00509
   PubMed Web of Science ®Google Scholar
• George-Chandy, A., Trysberg, E., & Eriksson, K. (2008). Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: Relationship to neuropsychiatric symptoms. Arthritis Research & Therapy, 10(4), R97. https://doi.org/10.1186/ar2484
   PubMed Web of Science ®Google Scholar
• Giordano, D., Kuley, R., Draves, K. E., Roe, K., Holder, U., Giltiay, N. V., & Clark, E. A. (2020). BAFF produced by neutrophils and dendritic cells is regulated differently and has distinct roles in antibody responses and protective immunity against west Nile virus. The Journal of Immunology, 204(6), 1508–1520. https://doi.org/10.4049/jimmunol.1901120
   PubMed Web of Science ®Google Scholar
• Gladman, D. D., Ibanez, D., & Urowitz, M. B. (2002). Systemic lupus erythematosus disease activity index 2000. The Journal of Rheumatology, 29(2), 288–291.
   PubMed Web of Science ®Google Scholar
• Hanly, J. G. (2004). ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. Lupus, 13(11), 861–864. https://doi.org/10.1191/0961203304lu2024oa
   PubMed Web of Science ®Google Scholar
• Hermosillo-Romo, D., & Brey, R. L. (2002). Diagnosis and management of patients with Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). Best Practice & Research Clinical Rheumatology, 16(2), 229–244. https://doi.org/10.1053/berh.2001.0223
   PubMed Web of Science ®Google Scholar
• Hopia, L., Thangarajh, M., Khademi, M., Laveskog, A., Wallstrom, E., Svenungsson, E., & Andersson, M. (2011). Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus. Scandinavian Journal of Rheumatology, 40(5), 363–372. https://doi.org/10.3109/03009742.2010.550900
   PubMed Web of Science ®Google Scholar
• Ibanez, D., Gladman, D., & Urowitz, M. (2007). Summarizing disease features over time: II. Variability measures of SLEDAI-2K. The Journal of Rheumatology, 34(2), 336–340.
   PubMed Web of Science ®Google Scholar
• Jarpa, E., Babul, M., Calderon, J., Gonzalez, M., Martinez, M. E., Bravo-Zehnder, M., Henríquez, C., Jacobelli, S., González, A., & Massardo, L. (2011). Common mental disorders and psychological distress in systemic lupus erythematosus are not associated with disease activity. Lupus, 20(1), 58–66. https://doi.org/10.1177/0961203310381773
   PubMed Web of Science ®Google Scholar
• Jin, S., Yu, C., & Yu, B. (2021). Changes of serum IL-6, IL-10 and TNF-α levels in patients with systemic lupus erythematosus and their clinical value. American Journal of Translational Research, 13(4), 2867–2874.
   PubMed Web of Science ®Google Scholar
• Lawson, B. R., Koundouris, S. I., Barnhouse, M., Dummer, W., Baccala, R., Kono, D. H., & Theofilopoulos, A. N. (2001). The role of αβ+ T cells and homeostatic T cell proliferation in Y-chromosome-associated murine lupus. The Journal of Immunology, 167(4), 2354–2360. https://doi.org/10.4049/jimmunol.167.4.2354
   PubMed Web of Science ®Google Scholar
• Lu, Z., Li, J., Ji, J., Gu, Z., & Da, Z. (2019). Altered peripheral lymphocyte subsets in untreated systemic lupus erythematosus patients with infections. Brazilian Journal of Medical & Biological Research, 52(4), e8131. https://doi.org/10.1590/1414-431x20198131
   PubMed Web of Science ®Google Scholar
• Luo, Q., Ye, J., Zeng, L., Li, X., Fang, L., Ju, B., Huang, Z., & Li, J. (2017). Elevated expression of TIGIT on CD3(+)CD4(+) T cells correlates with disease activity in systemic lupus erythematosus. Allergy, Asthma & Clinical Immunology, 13(1), 15. https://doi.org/10.1186/s13223-017-0188-7
   PubMedGoogle Scholar
• McCombie, A., Arnold, M., O’Connor, M., Stein, R., Fulforth, J., Brown, B., & Gearry, R. (2020). Why does pharmac neglect inflammatory bowel disease? The New Zealand Medical Journal, 133(1527), 111–115.
   PubMed Web of Science ®Google Scholar
• Mockel, T., Basta, F., Weinmann-Menke, J., & Schwarting, A. (2021). B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmunity Reviews, 20(2), 102736. https://doi.org/10.1016/j.autrev.2020.102736
   PubMed Web of Science ®Google Scholar
• Moore, E., Huang, M. W., & Putterman, C. (2020). Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus. Current Opinion in Rheumatology, 32(2), 152–158. https://doi.org/10.1097/BOR.0000000000000682
   PubMed Web of Science ®Google Scholar
• Moulton, V. R., & Tsokos, G. C. (2011). Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Research & Therapy, 13(2), 207. https://doi.org/10.1186/ar3251
   PubMed Web of Science ®Google Scholar
• Puthenparampil, M., Miante, S., Federle, L., Zanetta, C., Toffanin, E., Ruggero, S., Rinaldi, F., & Gallo, P. (2016). BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset. Journal of Neuroimmunology, 297, 63–67. https://doi.org/10.1016/j.jneuroim.2016.05.013
   PubMed Web of Science ®Google Scholar
• Qiao, X., Lu, L., Zhou, K., Tan, L., Liu, X., Ni, J., Hou, Y., Liang, J., & Dou, H. (2022). The correlation between proteoglycan 2 and neuropsychiatric systemic lupus erythematosus. Clinical Immunology (Orlando, Fla.), 239, 109042. https://doi.org/10.1016/j.clim.2022.109042
   PubMed Web of Science ®Google Scholar
• Ramskold, D., Parodis, I., Lakshmikanth, T., Sippl, N., Khademi, M., Chen, Y., Zickert, A., Mikeš, J., Achour, A., Amara, K., Piehl, F., Brodin, P., Gunnarsson, I., & Malmström, V. (2019). B cell alterations during BAFF inhibition with belimumab in SLE. E Bio Medicine, 40, 517–527. https://doi.org/10.1016/j.ebiom.2018.12.035
   Google Scholar
• Salazar-Camarena, D. C., Ortiz-Lazareno, P., Marin-Rosales, M., Cruz, A., Munoz-Valle, F., Tapia-Llanos, R., Orozco-Barocio, G., Machado-Contreras, R., & Palafox-Sánchez, C.A. (2019). BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus. Cytokine, 114, 115–127. https://doi.org/10.1016/j.cyto.2018.11.008
   PubMed Web of Science ®Google Scholar
• Salazar-Camarena, D. C., Ortiz-Lazareno, P. C., Cruz, A., Oregon-Romero, E., Machado-Contreras, J. R., Munoz-Valle, J. F., Orozco-López, M., Marín-Rosales, M., & Palafox-Sánchez, C. A. (2016). Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus. Lupus, 25, 582–592. https://doi.org/10.1177/0961203315608254
   PubMed Web of Science ®Google Scholar
• Samy, E., Wax, S., Huard, B., Hess, H., & Schneider, P. (2017). Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. International Reviews of Immunology, 36(1), 3–19. https://doi.org/10.1080/08830185.2016.1276903
   PubMed Web of Science ®Google Scholar
• Schweighoffer, E., & Tybulewicz, V. L. (2021). BAFF signaling in health and disease. Current Opinion in Immunology, 71, 124–131. https://doi.org/10.1016/j.coi.2021.06.014
   PubMed Web of Science ®Google Scholar
• Seyler, T. M., Park, Y. W., Takemura, S., Bram, R. J., Kurtin, P. J., Goronzy, J. J., & Weyand, C. M. (2005). BLyS and APRIL in rheumatoid arthritis. Journal of Clinical Investigation, 115(11), 3083–3092. https://doi.org/10.1172/JCI25265
   PubMed Web of Science ®Google Scholar
• Sharma, H., Bose, A., Sachdeva, R., Malik, M., Kumar, U., & Pal, R. (2022). Haemoglobin drives inflammation and initiates antigen spread and nephritis in lupus. Immunology, 165(1), 122–140. https://doi.org/10.1111/imm.13418
   PubMed Web of Science ®Google Scholar
• Smith, E. L., & Shmerling, R. H. (1999). The American college of rheumatology criteria for the classification of systemic lupus erythematosus: Strengths, weaknesses, and opportunities for improvement. Lupus, 8(8), 586–595. https://doi.org/10.1191/096120399680411317
   PubMed Web of Science ®Google Scholar
• Smulski, C. R., & Eibel, H. (2018). BAFF and BAFF-receptor in B cell selection and survival. Frontiers in Immunology, 9, 2285. https://doi.org/10.3389/fimmu.2018.02285
   PubMed Web of Science ®Google Scholar
• Stohl, W. (2014). Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opinion on Therapeutic Targets, 18(4), 473–489. https://doi.org/10.1517/14728222.2014.888415
   PubMed Web of Science ®Google Scholar
• Stohl, W., Metyas, S., Tan, S. M., Cheema, G. S., Oamar, B., Xu, D., Roschke, V., Wu, Y., Baker, K. P., & Hilbert, D. M. (2003). B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis & Rheumatism, 48(12), 3475–3486. https://doi.org/10.1002/art.11354
   PubMed Web of Science ®Google Scholar
• Stojan, G., Fang, H., Magder, L., & Petri, M. (2013). Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity. Lupus, 22(8), 827–834. https://doi.org/10.1177/0961203313492578
   PubMed Web of Science ®Google Scholar
• Subedi, A., Magder, L. S., & Petri, M. (2015). Effect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus. Rheumatology International, 35(10), 1687–1692. https://doi.org/10.1007/s00296-015-3265-6
   PubMed Web of Science ®Google Scholar
• Svenungsson, E., Andersson, M., Brundin, L., van Vollenhoven, R., Khademi, M., Tarkowski, A., Greitz, D., Dahlstrom, M., Lundberg, I., Klareskog, L., & Olsson, T. (2001). Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Annals of the Rheumatic Diseases, 60(4), 372–379. https://doi.org/10.1136/ard.60.4.372
   PubMed Web of Science ®Google Scholar
• Tsokos, G. C. (2011). Systemic lupus erythematosus. The New England Journal of Medicine, 365(22), 2110–2121. https://doi.org/10.1056/NEJMra1100359
   PubMed Web of Science ®Google Scholar
• Vincent, F. B., Northcott, M., Hoi, A., Mackay, F., & Morand, E. F. (2013). Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. Lupus, 22(9), 873–884. https://doi.org/10.1177/0961203313496302
   PubMed Web of Science ®Google Scholar
• Voll, R. E., Roth, E. A., Girkontaite, I., Fehr, H., Herrmann, M., Lorenz, H. M., & Kalden, J. R. (1997). Histone-specific Th0 and Th1 clones derived from systemic lupus erythematosus patients induce double-stranded DNA antibody production. Arthritis & Rheumatism, 40(12), 2162–2171. https://doi.org/10.1002/art.1780401210
   PubMedGoogle Scholar
• Yin, Y., Choi, S. C., Xu, Z., Perry, D. J., Seay, H., Croker, B. P., Sobel, E. S., Brusko, T. M., & Morel, L. (2015). Normalization of CD4+ T cell metabolism reverses lupus. Science Translational Medicine, 7(274), 274ra218. https://doi.org/10.1126/scitranslmed.aaa0835
   Web of Science ®Google Scholar
• Yu, H., Jiang, L., Yao, L., Gan, C., Han, X., Liu, R., & Su, N. (2018). Predictive value of the neutrophil‑to‑lymphocyte ratio and hemoglobin in systemic lupus erythematosus. Experimental and Therapeutic Medicine, 16, 1547–1553. https://doi.org/10.3892/etm.2018.6309
   PubMed Web of Science ®Google Scholar
• Zhang, J., Roschke, V., Baker, K. P., Wang, Z., Alarcon, G. S., Fessler, B. J., Bastian, H., Kimberly, R. P., & Zhou, T. (2001). Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. The Journal of Immunology, 166(1), 6–10. https://doi.org/10.4049/jimmunol.166.1.6
   PubMed Web of Science ®Google Scholar
• Zhang, S., Li, M., Zhang, L., Wang, Z., Wang, Q., You, H., Wang, Y., Li, M., & Zeng, X. (2021). Clinical features and outcomes of neuropsychiatric systemic lupus erythematosus in China. Journal of Immunology Research, 2021, 1–10. https://doi.org/10.1155/2021/1349042
   Web of Science ®Google Scholar
• Zhao, L. D., Li, Y., Smith, M. F., Wang, J. S., Zhang, W., Tang, F. L., Tian, X. P., Wang, H. Y., Zhang, F. C., Ba, D. N., He, W., & Zhang, X. (2010). Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus, 19(13), 1534–1549. https://doi.org/10.1177/0961203310375268
   PubMed Web of Science ®Google Scholar